Recurrent Endometrial Endometrioid Adenocarcinoma
8 clinical trials · Condition
◉ Watch Recurrent Endometrial Endometrioid Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (NCT03914612) | National Cancer Institute (NCI) | 2019-08-22 |
| Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer (NCT03348631) | National Cancer Institute (NCI) | 2019-05-01 |
| VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (NCT03120624) | Mayo Clinic | 2017-09-15 |
| Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer (NCT02684227) | M.D. Anderson Cancer Center | 2016-08-24 |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer (NCT00492778) | GOG Foundation | 2008-02-25 |
Track Recurrent Endometrial Endometrioid Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.